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Abstract
Introduction We examined the participation of a membrane
form of estrogen receptor (mER)-α in the activation of mitogen-
activated protein kinases (extracellular signal-regulated kinase
[ERK]1 and ERK2) related to cell growth responses in MCF-7
cells.
Methods We immunopanned and subsequently separated
MCF-7 cells (using fluorescence-activated cell sorting) into
mER-α-enriched (mERhigh) and mER-α-depleted (mERlow)
populations. We then measured the expression levels of mER-α
on the surface of these separated cell populations by
immunocytochemical analysis and by a quantitative 96-well
plate immunoassay that distinguished between mER-α and
intracellular ER-α. Western analysis was used to determine
colocalized estrogen receptor (ER)-α and caveolins in
membrane subfractions. The levels of activated ERK1 and ERK2
were determined using a fixed cell-based enzyme-linked
immunosorbent assay developed in our laboratory.
Results Immunocytochemical studies revealed punctate ER-α
antibody staining of the surface of nonpermeabilized mERhigh
cells, whereas the majority of mERlow cells exhibited little or no
staining. Western analysis demonstrated that mERhigh  cells
expressed caveolin-1 and caveolin-2, and that ER-α was
contained in the same gradient-separated membrane fractions.
The quantitative immunoassay for ER-α detected a significant
difference in mER-α levels between mERhigh and mERlow cells
when cells were grown at a sufficiently low cell density, but
equivalent levels of total ER-α (membrane plus intracellular
receptors). These two separated cell subpopulations also
exhibited different kinetics of ERK1/2 activation with 1 pmol/l
17β-estradiol (E2), as well as different patterns of E2 dose-
dependent responsiveness. The maximal kinase activation was
achieved after 10 min versus 6 min in mERhigh versus mERlow
cells, respectively. After a decline in the level of phosphorylated
ERKs, a reactivation was seen at 60 min in mERhigh cells but not
in mERlow  cells. Both 1A and 2B protein phosphatases
participated in dephosphorylation of ERKs, as demonstrated by
efficient reversal of ERK1/2 inactivation with okadaic acid and
cyclosporin A.
Conclusion Our results suggest that the levels of mER-α play a
role in the temporal coordination of phosphorylation/
dephosphorylation events for the ERKs in breast cancer cells,
and that these signaling differences can be correlated to
previously demonstrated differences in E2-induced cell
proliferation outcomes in these cell types.
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Introduction
Estrogen receptor (ER)-α has traditionally been defined as
a ligand-dependent transcription factor that regulates its
target genes by binding to estrogen response elements
present in the promoters of many responsive genes [1].
However, an ever-increasing number of reports indicate
that the cellular actions of estrogens can be initiated at the
plasma membrane, through membrane versions of estro-
gen receptors (mERs) [2-4] or via other membrane-resi-
dent 17β-estradiol (E2)-binding proteins [5]. There is also
evidence that mER-α from vascular endothelium and
human MCF-7 breast cancer cells is localized in special-
ized cholesterol-rich membrane microstructures (caveo-
lae), where it can associate with different signaling
CV = crystal violet; DCSS = medium with 4 × dextran-coated charcoal-stripped serum; E2 = 17β-estradiol; EGF = epidermal growth factor; ER = 
estrogen receptor; ERK = extracellular signal-regulated kinase; FACS = fluorescence-activated cell sorting; OA = okadaic acid; MAPK = mitogen-
activated protein kinase; MEK = mitogen-activated protein kinase kinase; mER = membrane estrogen receptor; pNp = paranitrophenol; PP = protein 
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molecules and participate in various nongenomic actions
[6,7].
A variety of rapid E2-induced signal transduction events
can lead to stimulation of calcium flux, cAMP production,
phospholipase C activation, and inositol phosphate pro-
duction [8]. Mitogen-activated protein kinases (MAPKs)
such as extracellular signal-regulated kinase (ERK)1 and
ERK2 are also rapidly stimulated by estrogens in various
cell types (e.g. endothelial [9], osteoblastic [10], neuroblas-
toma [11], and breast cancer cells [12]). However, the spe-
cific relationship of these responses to the levels of
antibody-identified ER-α in the membrane has rarely been
investigated [13,14]; other rapid estrogen-induced actions
were specifically linked to mER-α in pituitary tumor cells in
our previous studies [15-18].
The two isoforms of ERK (p42 and p44) play critical roles
in the control of cell proliferation, differentiation, homeosta-
sis, and survival. Traditionally, autophosphorylation of
receptor tyrosine kinases after ligand binding initiates the
cascade of phosphorylation steps that result in dual ERK
phosphorylation (on Thr202 and Tyr204 in the human
enzyme, or Thr183 and Tyr185 in the rat enzyme [19]). The
signaling pathway initiated by E2 at the level of the plasma
membrane is not yet completely understood, although
recent studies have implicated a cascade of intermediary
proteins and signaling steps involving mER-α, G-proteins,
Src-induced matrix metalloproteinases that liberate
heparin-binding epidermal growth factor (EGF), and EGF
receptor [13]; the involvement of many other signaling
pathways remains unexamined.
Whether different levels of mER can influence signaling
parameters (such as kinetics and final levels of second
messengers) that lead to physiological responses remains
to be investigated. To address this question we separated
MCF-7 cells into two subpopulations based on outer mem-
brane-exposed mER-α levels and confirmed their differen-
tial mER-α expression by several methods. We investigated
the association of mER-α with caveolin-rich membrane
fractions in cells enriched for membrane display of these
receptors. We then linked the level of mER-α to the magni-
tude and patterns of E2-induced ERK1/2 activation.
Although activation of kinases was previously demon-
strated, those other studies did not address the accompa-
nying inactivation mechanisms for ERKs involving several
specific cellular phosphatases.
Methods
Cell immunoseparation and subculturing
Our MCF-7 cells originated from the Michigan Cancer
Center. We separated them into two subpopulations by
immunopanning [16,20] using C-542 carboxyl-terminal ER-
α antibody provided by Drs Dean Edwards and Nancy
Weigel; this antibody is now commercially available from
Stressgen Biotechnologies (Victoria, Canada). Briefly, ster-
ile antibody on the surface of a petri plate bound cells over
a 1-hour time period at 4°C, and cells that attached to the
plate (mER+) were propagated separately from those that
did not bind (mERlow). The mER+ cells were then subjected
to further selection via fluorescence-activated cell sorting
(FACS) using the same antibody [21]. Cells undergoing
sequential separation were highly enriched for mER-α
(mERhigh). All cell subpopulations were routinely cultured in
phenol-red free Dulbecco's modified eagle medium
(Gibco-BRL, Grand Island, NY, USA) supplemented with
10% heat-inactivated DSCS (defined/supplemented
bovine calf serum; HyClone Laboratories Inc., Logan, UT,
USA) and 1% of an antibiotic–antimycotic (Gibco Invitro-
gen Corporation, #15240-062). Cells used in the experi-
ments were between passage 8 and 14 after separation.
Three days before each experiment, the cell growth
medium was replaced with medium containing 4 × dextran-
coated charcoal stripped serum (DCSS medium) or com-
pletely defined medium (DM; phenol-red free Dulbecco's
modified eagle medium with 5 µg/ml each of insulin and
transferrin, 5 ng/ml selenium, and 0.1% bovine serum albu-
min). Stripped serum was produced by incubation with an
equivalent volume of packed 0.25% weight/vol charcoal
Norit A for 2 hours on a shaker at 4°C. The charcoal prep-
aration had previously been suspended in 0.0025%
(weight/vol) dextran T-70 (Sigma-Aldrich, St. Louis, MO,
USA) in 0.25 mol/l sucrose, 1.5 mmol/l MgCl2, and 10
mmol/l HEPES (pH 7.6). The charcoal was pelleted at 500
g for 10 min, the supernatant (stripped serum) decanted,
and the process repeated a total of four times.
Fluorescence immunocytochemical detection of 
membrane ER-α
The protocol published for immunocytohcemical detection
of mER-α in the GH3 rat pituitary cell line [22] was opti-
mized for MCF-7 cells. Briefly, the cells were fixed in 2%
paraformaldehyde/0.1% glutaraldehyde in phosphate-buff-
ered saline for 25 min at room temperature; those condi-
tions preserve the integrity of the cell membrane and
enable detection of the specific ER-α antibody bound to
the cell surface without interference from the usually more
intense nuclear signal. Autofluorescence was reduced by
blocking the aldehyde groups for 15 min with 1%
Na2HPO4 and 0.05% NaBH4. Nonspecific binding sites
were blocked with 0.1% fish gelatin in phosphate-buffered
saline for 45 min at room temperature, which we success-
fully used previously in GH6/B6/F10 cells [23,24]. For the
present studies with MCF-7 cells, we compared the non-
specific antibody signal blocking abilities of fish gelatin,
horse serum, bovine serum albumin and nonfat dry milk, all
commonly used methods, and found them to be equally
useful.Available online http://breast-cancer-research.com/content/7/1/R130
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The plates were incubated with C-542 antibody (5–10 µg/
ml) overnight at 4°C in the blocking solution. To detect the
bound primary antibody and amplify the signal, we used a
biotinylated secondary antibody from the biotin/avidin
Vectastain ABC-Alkaline Phosphatase kit and Vector red
as a substrate, together with 40 µl of 125 mmol/l levamisol
(which inhibits the endogenous alkaline phosphatases). All
the components for detection of bound primary antibody
were obtained from Vector Laboratories Inc. (Burlingame,
CA, USA). Fluorescence photography was performed as
previously described [15,22]. The images were photo-
graphed with Kodak HC4000 color film and a camera
(Model C-35AD-4) with Olympus AHBT microscope and
fluorescence attachment (model AH2-RFL) using the FITC
filter, under 100 × magnification. Digital deconvolution and
pseudo-coloring were performed with Image-Pro Plus soft-
ware applied to images captured through the FITC filter
with a CoolSNAP-Pro digital monochrome camera and a
ProScan motorized stage (Meyer Instruments, Houston,
TX, USA) attached to a Olympus AHBT microscope
equipped with fluorescence attachments (model AH2-
RFL).
Quantification of membrane ER-α
The mER was quantified with a protocol modified from one
previously developed in our laboratory for GH3 cells [23].
Briefly, cells plated and treated in 96-well plates were fixed
as described for immunocytochemistry (see above), and
the integrity of the membrane was verified by lack of stain-
ing with the anti-clathrin antibody (ICN Biomedicals,
Aurora, OH, USA), as clathrin is localized just inside the
plasma membrane. Different concentrations of C-542 ER-
α antibody were tested (in the range 1–12 µg/ml), and the
tagging enzymatic reaction (alkaline phosphatase) was
monitored for different time intervals (5, 15 and 30 min) in
order to determine optimal conditions for measurement.
The specificity of the C-542 antibody was checked by com-
paring its binding with the nonspecific binding of mouse
IgG1k (mIgG1k, of the same immunoglobulin isotype) and by
the ability of the peptide representing the C-542 epitope
(Genosys, Woodlands, TX, USA) to decrease C-542 bind-
ing. Other controls included incubation without any anti-
body to detect endogenous phosphatase not inhibited by
levamisol, and without primary antibody to detect nonspe-
cific binding of secondary antibody. The total cellular ER-α
was measured by applying the same procedure to cells
permeabilized by including 0.1% of the non-ionic detergent
IGEPAL CA-630 (Sigma-Aldrich) during the fixation proce-
dure. The absorbance of the alkaline phosphatase product
paranitrophenol (pNp) in each well was measured at 405
nm and normalized against the number of cells determined
by the absorbance of crystal violet (CV) at 590 nm, as pre-
viously described [23].
Caveolae preparation and Western analysis
To concentrate caveolin-rich membranes, we extended a
previously published protocol [25] by introducing a dialysis
step to remove sucrose, and a vacuum spin at a low drying
rate to concentrate the samples. Specifically, cells were
seeded in three 150 mm diameter plates and grown in
serum-supplemented medium until 60% confluent. The
growth medium was replaced with DCSS medium devoid
of antimycotic compound and cultured for an additional 3
days. Cells from all three plates were collected in 1 ml lysis
buffer consisting of 50 mmol/l Tris/HCl (pH 7.5), 5 mmol/l
EDTA, 100 nmol/l NaCl, 50 mmol/l NaF, 1 mmol/l PMSF,
0.2% TritonX-100 and protease inhibitor cocktail P8340
(100 × diluted; Sigma-Aldrich). Cells in solution were
passed through a 25-g syringe needle, then homogenized
with 25 strokes using a Dounce B-type pestle. The
homogenate was adjusted to 45% sucrose by addition of
an equivalent volume of 90% sucrose. A discontinuous
sucrose gradient consisting of the sample, 35% sucrose,
and a top layer of 5% sucrose was centrifuged for 18 hours
at 200,000 g. Fractions of 1 ml were collected and
checked for the presence of caveolin-1 and caveolin-2 by
Western analysis using antibodies from Biosciences (San
Jose, CA, USA). Fractions 5 and 6 (the interface between
5% and 35% sucrose) contained the highest amount of
caveolin-1. Those two fractions were pooled and dialyzed
overnight against the lysis buffer. The sample was then
concentrated by vacuum spin, and 20 µg of these proteins
separated by 4–20% SDS-PAGE. The proteins were trans-
ferred to nitrocellulose membranes and the mER-α bands
were probed with C-542 ER-α antibody. After incubation
with secondary antibody (conjugated with horse radish per-
oxidase) the bands were visualized with an ECL kit (Amer-
sham Pharmacia Biotech, Piscataway, NJ, USA).
Fixed cell-based enzyme-linked immunosorbent assay 
detection of activated ERK1/2 in 96-well plates
A protocol previously developed in our laboratory for other
cells [26] was optimized for MCF-7 cells. Cells were plated
at a density of 4000/well in 96-well plates, and after 24
hours the growth medium was replaced with DCSS
medium. After 3 more days of culture the cells were treated
with E2 (1 pmol/l) for different time intervals (3, 6, 10, 20,
30 and 60 min), or with different E2 concentrations (from
10-16 to 10-7 mol/l) for 10 and 6 min for mERhigh and mERlow
cells, respectively. After treatments the cells were fixed in
2% paraphormaldehyde/0.21% picric acid for 2 days at
4°C. The cells were subjected to a 60 min blocking step
with 0.1% fish gelatin and 0.1% Triton X-100 at room tem-
perature. Incubation with the antibody raised against the
phosphorylated forms of ERK1/2 (Cell Signaling Technol-
ogy, Beverly, MA, USA) was performed overnight at 4°C
(1:400 dilution). To quantify active ERKs, biotinylated sec-
ondary antibody (anti-mouse/anti-rabbit) conjugated to
alkaline phosphatase was applied. Substrate pNpBreast Cancer Research    Vol 7 No 1    Zivadinovic and Watson 
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phosphate was added and incubated for 25 min at 37°C,
and the absorbance of the pNp product was determined at
405 nm in a plate reader (Wallac 1420; Perkin Elmer, Bos-
ton, MA, USA). The levels of phosphorylate (pERK1/2)
were normalized to the cell number in each well (measured
using the CV assay).
To confirm the activation of ERK1/2 (after 3, 6 and 10 min
in mERhigh or 6 min in mERlow), we pretreated the cells for
15 min with 40 µmol/l U0126 MEK1/2 inhibitor (Cell Sign-
aling Technology). The ER antagonist ICI182,780 (Tocris
Cookson Inc., Ellisville, MO, USA) at a concentration of 1
µmol/l was tested with or without E2 by preincubating the
cells with ICI182,780 for 30 min followed by the addition
of 1 pmol/l E2 or by simultaneous addition of ICI182,780
and E2. MDA-MB-231 cells used to test the requirement of
ER-α for these responses were obtained from ATCC (Man-
assas, VA, USA). We confirmed the absence of ER-α
mRNA in these cells by multiple reverse transcription
polymerase chain reaction primer pairs representing the
ER-α sequence (data not shown).
Cell proliferation
Cells were plated at a density of 1000 cells/well in 96-well
plates. The next day the growth medium was replaced with
DCSS containing different treatments. The 1 pmol/l E2 was
present either for the duration of the experiment or as a
short pulse treatment (10 min), whereas 1 pmol/l E2-perox-
idase (Sigma-Aldrich; concentration based on the E2 con-
tent of the conjugate) was used only as short pulse
treatment. The effect of MEK inhibitor (40 µmol/l U0126)
on the pulsed E2-induced proliferation of mERhigh cells was
tested by a pretreatment for 15 min and an additional treat-
ment for 10 min with E2 together with the inhibitor. To block
the effect of E2 in the pulse treatment, we used ER-α anti-
body (AER315; NeoMarkers Inc., Fremont, CA, USA)
raised against the ligand-binding domain. The cells were
pretreated with 1 µg/ml AER315 antibody for 1 hour at
room temperature, followed by a 10 min incubation at 37°C
with 1 pmol/l E2 in the presence of the antibody. Controls
for E2 treatment were done on a separate plate, because
we previously determined that low amounts of volatilized
estrogens can affect responses mediated via nongenomic
signaling pathways [24]. After 5 days the cells were fixed
with 2% paraformaldehyde/0.1% glutaraldehyde in phos-
phate-buffered saline in preparation for the CV assay (see
below).
Crystal violet assay
The number of the cells in each well was determined with
the CV assay [27], which we modified previously [23].
Fixed cells were incubated in 0.1% filtered CV solution for
30 min at room temperature, and excess dye was removed
by three brief rinses with ddH2O. The plates were then air
dried, the dye was extracted with 10% acetic acid, and the
extract (in the same wells) was then read in a plate reader
(Wallac 1420, Perkin Elmer) at 590 nm. The utility of this
assay was previously verified for GH3B6 cells by compari-
son with other assays of cell number in combination with
the immunoplate assays [23]. In addition, for MCF-7 cells
we verified the utility of this assay for measuring cell
number by comparison with DNA content measurements
and with cell counts by hemocytometer (data not shown).
We also compared the CV assay with the MTT assay,
which is often used to determine viable cell number
(ATCC), and we obtained a linear correlation for the two
assays. These latter results are presented in the accompa-
nying paper [28].
Statistical analysis
Statistical differences between two sets of data were
determined using two-way analysis of variance. The differ-
ences between the entire curves were tested by comparing
the sum of squares of the residuals from each individual
curve with the sum of squares of the residuals of the com-
bined curve by applying a Microsoft Excel F test. P < 0.05
was considered statistically significant.
Results
Immunoseparated cell characterization of mER-α
Immunopanning and subsequent FACS successfully sepa-
rated MCF-7 cells into two populations according to the
expression of mER-α observed in immunocytochemistry
experiments. Punctate staining can be seen on the surface
of unpermeabilized mERhigh cells (Fig. 1a), whereas the
majority of mERlow cells did not exhibit this staining (Fig.
1b). Whenever occasional staining was present on cells in
the mERlow population, its appearance was similar to that
seen on mERhigh cells (data not shown). Secondary anti-
body staining alone was at levels similar to that shown for
the mERlow cells in Fig. 1b (not shown). When permeabi-
lized, both subpopulations of cells exhibited plentiful cyto-
plasmic and nuclear staining (not shown) at similar levels.
Digital deconvolution (in 15 separate cell planes) per-
formed on a grouping of three unpermeabilized mERhigh
cells clearly demonstrated punctuate staining all along the
periphery of these cells (Fig. 2).
To determine whether mER-α is in a submembrane location
in our mER-α-enriched cells, we colocalized mER-α with
caveolin proteins in gradient-separated membrane frac-
tions. Our mERhigh cells express both caveolin-1 (form α
and β represented by doublet bands) and caveolin-2 (Fig.
3a; two different concentrations of protein were loaded in
adjacent lanes). In the same density gradient fractions that
contained the majority of these caveolar structural proteins
(fractions 5 and 6), mER-α was found (Fig. 3b). We
detected several prominent bands from both the sucrose
gradient fractions (fractions 5 and 6) and the whole cell
lysates (Fig. 3b, panel 1). To determine those bands whoseAvailable online http://breast-cancer-research.com/content/7/1/R130
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signal was specific for C-542 ER-α antibody, we performed
an epitope competition (preblocking of antibody with pep-
tide representing the epitope). We identified two ER-α
bands competable with peptide: the 67 kDa (the size of
classical ER-α) and a prominent lower band at 52 kDa (Fig.
3b, compare panels 1 and 2).
To quantify mER-α with our plate assay, we first determined
the lowest optimal C-542 antibody concentration that
would saturate binding to the membrane form of the recep-
tor, and then optimized assay conditions to give a reliably
detectable signal in the linear range of the fluorescent prod-
uct assay. All three signal generation incubation times (5,
15 and 30 min) gave acceptable data, but 15 min assays
allowed clear delineation of antigen-saturating concentra-
tions of C-542 antibody utilizing lower antibody concentra-
tions (8 µg/ml; Fig. 4a). Those conditions were used for
subsequent assays. The same level of mER-α could be
detected in cells kept for 3 days in a completely defined
medium lacking serum or in the same medium supple-
mented with 10% DCSS (Fig. 4a, open circles and closed
circles, respectively). The background values (obtained in
the absence of primary and secondary antibody, or with no
primary antibody) were very low (Fig. 4b). At 8 µg/ml the
isotype control mIgG1k yielded a value only 10% of that for
C-542 antibody; peptide competition resulted in an approx-
imate 50% decrease in C-542 antibody binding, again
verifying the specificity of the antibody for this epitope. This
verified that the assay was specific, and not subject to inter-
ference by endogenous alkaline phosphatases in the pres-
ence of levamasole. The fixation conditions that we used
preserved the integrity of the cell membrane, as demon-
strated by the negligible anti-clathrin antibody binding in
nonpermeabilized versus the very high binding in permeabi-
lized cells. Therefore, equivalent protocols differing only in
the inclusion of a permeabilization agent during fixation can
be used to quantify the total ER (tER) versus the mER.
Because we had previously observed an effect of cell den-
sity on the level of ER expression in GH3/B6/F10 cells,
which occurred at a density when cells had just begun to
make contact by cell processes [24], we wondered
Figure 1
Fluorescence immunocytochemical detection of membrane estrogen  receptor (mER)-α in nonpermeabilized MCF-7 cells Fluorescence immunocytochemical detection of membrane estrogen 
receptor (mER)-α in nonpermeabilized MCF-7 cells. Cells were fixed 
with 2% pararaformaldehyde/0.1% glutaraldehyde, probed with C-542 
carboxyl-terminal estrogen receptor-α antibody, and visualized with a 
biotinylated secondary antibody–avidin conjugated alkaline phos-
phatase fluorescent Vector red product. Fluorescence images were 
photographed using the FITC filter and 100 × magnification. (a) mER-
α-enriched (mERhigh) MCF-7 cells; the arrows indicate some of the 
punctate staining. (b) mER-α-depleted (mERlow) MCF-7 cells have no 
staining. The bar in panel b represents 10 µm.
Figure 2
Digital deconvolution of membrane estrogen receptor (mER)-α fluores- cent image in mER-α-enriched (mERhigh) MCF-7 cells Digital deconvolution of membrane estrogen receptor (mER)-α fluores-
cent image in mER-α-enriched (mERhigh) MCF-7 cells. Fifteen different 
focal planes starting from the top of the cells and moving toward the 
bottom are displayed. The sequential slices are from left to right in each 
row of images. These cells are nonpermeabilized and treated as 
described in the previous figure legend. The corresponding transmitted 
light image is displayed in the upper left-hand corner. FITC filter images 
were captured, pseudo-colored, and processed by digital 
deconvolution.Breast Cancer Research    Vol 7 No 1    Zivadinovic and Watson 
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whether the same regulation was applicable to breast
cancer cells. Considering this effect, plating a single den-
sity may not demonstrate the ability of cells to express
mER-α. Therefore, we performed a cell density study for
mERhigh versus mERlow breast cancer cell types (Fig. 5).
The mER-α signal decreased exponentially with increasing
cell number (Fig. 5a). At low plating densities, mERhigh cells
clearly showed much higher levels of mER than did mERlow
cells (Fig. 5, closed circles and open circles, respectively).
The two curves approximating the level of mER were signif-
icantly different (P = 0.0003). The ER-α-negative cell line
MDA-MB-231 did not have mER-α (Fig. 5, diamond), even
at relatively low cell density, because their value was at the
level of mIgG1k isotype control antibody levels (horizontal
hatched line). Increased cell density also decreased tER
(Fig. 5b); however, mERhigh and mERlow MCF-7 cells exhib-
ited the same level of tER, because all of these data could
be approximated with the same curve. Because mERhigh
cells had higher mER-α levels but the same tER-α levels as
mERlow cells, then, by subtraction, mERhigh cells have lower
intracellular ER-α levels than do mERlow cells.
Figure 3
Identification of membrane estrogen receptor (mER) in caveolae by  Western blot analysis Identification of membrane estrogen receptor (mER) in caveolae by 
Western blot analysis. (a) Caveolin-1 (upper panel) and caveolin-2 
(lower panel) in MCF-7 cell membranes. Membrane fractions containing 
caveolae were separated on discontinuous sucrose gradients. Frac-
tions 5 and 6 were combined and 20 and 40 µg/ml protein (shown by 
adjacent lanes with connecting bar) were resolved on a 4–20% SDS-
polyacrylamide gel, transferred to a nitrocellulose membrane, and 
probed with specific antibodies. Fractions from human endothelial (HE) 
and mouse fibroblast (RSV-3T3) cells were used as positive controls 
(50 µg/ml protein). (b) Whole cell lysates (GH3, MCF-7) and pooled 
membrane fractions 5 and 6 (Fr.5+6) from sucrose gradients for MCF-
7 cells were probed with estrogen receptor-α-specific antibody C-542 
(panel 1) or the same antibody blocked with the epitope peptide (panel 
2). The arrows show the positions of major bands that were identified 
as receptor by epitope competition (at 67 and 52 kDa).
Figure 4
Optimization of 96-well plate immunoassay for membrane estrogen  receptor (mER) quantification in MCF-7 cells Optimization of 96-well plate immunoassay for membrane estrogen 
receptor (mER) quantification in MCF-7 cells. (a) Different concentra-
tions of estrogen receptor-α-specific C-542 antibody (1–12 µg/ml) 
were tested. Enzymatic paranitrophenol phosphate (pNpp) hydrolysis 
yielding the paranitrophenol (pNp) product was monitored at 37°C for 
5, 15 and 30 min, as shown. Cells pretreated for 72 hours with medium 
containing dextran-coated charcoal-stripped serum (DCSS) versus 
defined medium (DM) are represented with closed and open circles, 
respectively. (b) Antibody binding compared in nonpermeabilized (open 
bars) and permeabilized (shaded bars) conditions. no1°no2° represents 
primary and secondary antibodies omitted; no1° represents primary 
antibody omitted (only secondary antibody applied); mIgG1k repre-
sents mouse IgG1k isotype control; peptide comp. represents C-542 
epitope peptide blocking of the interaction with primary antibody; anti-
clathrin represents our test for cell membrane integrity. Values are 
expressed as means ± standard error. CV, crystal violet.Available online http://breast-cancer-research.com/content/7/1/R130
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Kinetics of ERK1/2 activation by 17β-estradiol in MCF-7 
cells enriched and MCF-7 cells depleted for membrane 
ER-α
During the optimization of the fixed cell-based enzyme-
linked immunosorbent assay for ERK activation, we estab-
lished the optimal cell density for a 10 min EGF treatment,
which is known to result in substantial phosphorylation of
ERK1/2. Both the controls and EGF-treated cells exhibited
increased pERK1/2 with increased cell number (Fig. 6a,
main graph). As we expected, normalizing pERK1/2 values
to the number of cells (CV absorbance at 590 nm) did not
significantly change the ratio values except in the case of
the highest number of cells plated, verifying that cells
plated in the density range of CV values 0.2–0.6 could be
used. Partly because others have shown that ERKs can be
activated by mechanical stimulus in MCF-7 cells [29], we
tested ethanol-treated controls over the same time course
(3–60 min). A pronounced decrease in ERK1/2 phosphor-
ylation was seen with time (Fig. 6b), and so appropriate
controls were performed for each time point in all subse-
quent experiments.
In mERhigh MCF-7 cells, ERK1/2 activation with 1 pmol/l E2
was fast and transient (Fig. 7a). The maximal activation was
achieved after 10 min, followed by a rapid decline in phos-
phorylated ERK1/2. However, continued incubation with E2
(1 hour) resulted in the reactivation of ERK1/2. To test
whether this signal was initiated at the membrane, the
impeded ligand E2-peroxidase was applied to the cells at
steroid concentrations that approximated the levels applied
as free steroid in the previous experiments (Fig. 7b). To
eliminate any free steroid present, just before use we pre-
treated the E2-peroxidase with dextran-coated charcoal
under conditions that remove more than 99% of free hor-
mone [9]. The resulting maximal level of ERK1/2 activation
was slightly higher than for treatment with the free ligand,
but the peak time of activation was the same. Again, a
recurrent later ERK activation was observed.
Cells with lower levels of mER-α (Fig. 7c) also had the
capacity for fast and transient activation of ERK1/2, but this
smaller activation peak appeared at 6 min after 1 pmol/l E2
treatment. The levels of phosphorylated ERK declined
between 10 and 30 min of E2 treatment as they had with
mERhigh cells; however, at longer incubations (1 hour) no
reactivation was seen but rather a further ERK1/2 apparent
dephosphorylation was observed. This implies that higher
levels of mER-α associated with more robust early ERK
activation are also responsible for the sustained ERK reac-
tivation at the later stage.
The inhibitor of the upstream MEK1/2, namely U0126, was
effective in inhibiting ERK1/2 activation in both types of
MCF-7 cells (Fig. 6a and 6c, insets), verifying that the val-
ues we measured in our plate assay were from MEK-phos-
phorylated ERK. In the MDA-MB-231 ER-α-negative cell
line (Fig. 7d), E2 could not significantly activate ERK1/2,
confirming that ER-α is necessary for ERK activation during
this 60 min time period.
Figure 5
Quantification of membrane estrogen receptor (mER) and total estro- gen receptor (tER) in mER-α-enriched (mERhigh) and mER-α-depleted  (mERlow) MCF-7 cells Quantification of membrane estrogen receptor (mER) and total estro-
gen receptor (tER) in mER-α-enriched (mERhigh) and mER-α-depleted 
(mERlow) MCF-7 cells. (a) Different numbers of cells were fixed in the 
same manner as described in Fig. 1 and the level of mER was assessed 
with 8 µg/ml C-542 antibody. Closed and open circles represent mER-
high and mERlow cells, respectively. The data were approximated with an 
exponential decay curve and compared by evaluating the difference 
between the sums of squares of the residuals from each curve with the 
sum of squares of the residuals for the combined curve using the F-test. 
The curves are significantly different (P = 0.0003). The diamond repre-
sents MDA-MB-231 cells and the cross-hatched horizontal bar the level 
of binding of a mouse IgG1k isotype control antibody. (b) Level of total 
ER (intracellular estrogen receptor [iER] plus mER) for mERhigh (closed 
circles) and mERlow (open circles) under the same binding conditions 
except for permeabilization of the cells. Where error bars for standard 
error are not visible, they are smaller than the size of the symbols. CV, 
crystal violet; pNp, paranitrophenol.Breast Cancer Research    Vol 7 No 1    Zivadinovic and Watson 
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Dose-dependent activation of ERK1/2 by 17β-estradiol is 
influenced by the level of membrane ER-α expression
In mERhigh cells, the ability of E2 to induce ERK activation
was biphasic with respect to dose at the 10 min time point
(early response peak). ERK phosphorylation was stimu-
lated at a wide range of concentrations from 0.1 pmol/l to
100 nmol/l E2, although the highest E2 concentrations
resulted in less phosphorylation (Fig. 8a). In mERlow cells a
biphasic response was also seen, but the only effective
concentrations were 0.1 and 1 pmol/l for the 6 min (early
and only) response peak (Fig. 8b).
Physiologic significance of early ERK1/2 activation
Long-term treatment of mERhigh MCF-7 cells with 1 pmol/l
E2 resulted in substantial stimulation of proliferation (Fig. 9).
A 10 min short pulse treatment also resulted in significant
although lower stimulation of proliferation. The same level
of stimulation was achieved with both E2 and E2-peroxidase
presented for a short pulse. E2-induced proliferation was
prevented with MEK inhibitor (U0126) as well as with a
specific ER-α antibody recognizing the ligand binding
domain. These results are consistent with the participation
of mER-α and ERK1/2 in the cell proliferation response.
Phosphatase inhibitors differentially affect ERK 
activation in MCF-7 cells enriched and depleted for 
membrane ER-α
We next asked whether the observed decrease in phos-
phorylated ERK1/2 after 20 min in both subpopulations of
cells, and the continued low phosphorylation levels after 60
min in mERlow cells, could successfully be abrogated with
specific phosphatase inhibitors (Fig. 10). We tested
inhibitors of protein phosphatase (PP)1, PP1A, and PP2B.
These phosphatases can be considered principal enzymes
of this class, based on their general abundance and broad
specificity [30]. Okadaic acid (OA), an inhibitor of PP1 and
PP1A, and cyclosporin A, an inhibitor of PP2B, were both
able to reverse the ERK inactivation in mERhigh cells (Fig.
10a). In mERlow cells, both the 20 min and continued 60
min dephosphorylation were abrogated only with the PP2B
inhibitor (Fig. 10b and 10c). Because of the known apop-
totic effect of OA at some concentrations [31], it is impor-
tant to stress that we applied it at a low concentration (50
nmol/l). In addition, OA does not have toxic effects in short-
term incubations [32]. These results suggest that dephos-
phorylation of ERKs is an important component of their
process of action and that coordinated phosphorylation/
dephosphorylation is required for strong signaling through
this pathway.
Rapid effects of ICI182,780 and 17α-estradiol on ERK1/2 
activation
To characterize the pharmacologic properties of ERK acti-
vation, we used mERhigh cells to study the effectiveness of
the potent antiestrogen ICI182,780 (1 µmol/l) and the
inactive E2 stereoisomer 17α-estradiol (10 nmol/l). We
used concentrations of these compounds shown by others
to be effective in inhibiting the transcriptional activity of E2.
We had also previously shown that a 10 nmol/l 17α-estra-
diol concentration could elicit another type of nongenomic
Figure 6
Optimization of fixed cell-based enzyme-linked immunosorbent assay  for mitogen-activated protein kinase using epidermal growth factor  (EGF) stimulation Optimization of fixed cell-based enzyme-linked immunosorbent assay 
for mitogen-activated protein kinase using epidermal growth factor 
(EGF) stimulation. (a) Different numbers of cells were treated for 10 
min with 50 ng/ml EGF, fixed, and the level of extracellular signal-regu-
lated kinase (ERK)1/2 phosphorylation determined using a phospho-
specific antibody and the Vectastain ABC alkaline phosphatase kit with 
paranitrophenol phosphate (pNpp) substrate. Inset: values for parani-
trophenol (pNp) normalized against the number of cells determined by 
the crystal violet (CV) assay. Closed and open circles represent EGF 
and vehicle treatment, respectively. (b) Time course of ERK stimulation 
by vehicle. Open circle: zero time point estimated by averaging 20, 30 
and 60 min values of vehicle treatment. Asterisks indicate significant 
differences (P < 0.05) compared with all other values. Values are 
expressed as means ± standard error.Available online http://breast-cancer-research.com/content/7/1/R130
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estrogenic effect in our GH3/B6/F10 pituitary tumor cell
model – rapid prolactin release [15]. ICI182,780 alone
induced an activation pattern very similar to that seen with
E2  but with an earlier first peak (Fig. 11a). A 30 min
ICI182,780 preincubation before a subsequent 1 pmol/l E2
challenge did not significantly change the E2 activation pat-
tern, although the first peak again appeared at 6 min (the
ICI182,780 pattern) and there was a much more pro-
nounced inactivation at 10 and 20 min (compare Fig. 11b
with Figs 7a and 11a). However, simultaneous application
of ICI182,780 (1 µmol/l) and E2 (1 pmol/l) blunted the
response and altered the kinetics of ERK phosphorylation,
shifting the now single weak activation to later times (20–
60 min; Fig. 11c). The E2 stereoisomer (17α-estradiol) pro-
voked a slightly delayed and blunted response also, but
with some other interesting features (Fig. 11d). A signifi-
cant dephosphorylation occurred before the major activa-
tion peak, a return to baseline phosphorylation levels
followed the 20 min activation peak, and no second activa-
tion peak occurred at 60 min.
Discussion
In the late 1970s, Pietras and Szego [33] reported the
presence of high-affinity binding sites for E2 associated
with the plasma membranes of the MCF-7 human breast
cancer cell line. Since that time few laboratories have fol-
lowed up on this finding [34,35] until very recently, when
more detailed studies started to emerge. However, none of
these studies established a correlation between the level of
identified mER-α expression and its functions.
To address this issue we used immunopanning followed by
FACS to separate MCF-7 cells into two subpopulations
that were enriched and depleted for mER-α expression.
We then used several approaches to assess the appear-
ance and levels of mER-α in these two subpopulations.
These studies demonstrated that MCF-7 cells are hetero-
geneous with respect to mER-α expression, and that
difficulties in reproducibly demonstrating nongenomic
estrogenic effects in these cells could in part be due to the
dilution of responding cells in the largely nonresponsive
total cell population. We were able to obtain two distinct
cell subpopulations without applying plasmid-based trans-
Figure 7
Time course of extracellular signal-regulated kinase (ERK)1/2 activation with 17β-estradiol (E2) and impeded ligand in membrane estrogen receptor  (mER)-α-enriched (mERhigh) and mER-α-depleted (mERlow) MCF-7 cells, and receptor-less cells Time course of extracellular signal-regulated kinase (ERK)1/2 activation with 17β-estradiol (E2) and impeded ligand in membrane estrogen receptor 
(mER)-α-enriched (mERhigh) and mER-α-depleted (mERlow) MCF-7 cells, and receptor-less cells. After 72 hours in medium with dextran-coated char-
coal-stripped serum (DCSS), cells were treated with 1 pmol/l E2, or an equivalent concentration of hormone contained in an E2-peroxidase conju-
gate, for different time intervals. (a, b) mERhigh MCF-7 cells treated with E2 and E2-peroxidase, respectively. (c) mERlow MCF-7 cells treated with E2. 
(d) Estrogen receptor-α-negative MDA-MB-231 cells treated with E2. Each experiment was repeated at least three times, each time point represents 
16 replicate wells, and the values are expressed as mean ± standard error. Insets: inhibition of ERK1/2 activation with U0126 upstream mitogen-
activated protein kinase kinase (MEK)1/2 inhibitor. The cells were pretreated for 15 min with 40 µmol/l inhibitor (gray bars) and E2-induced activa-
tion of ERK1/2 was tested at activation times appropriate for each cell type (after 3, 6 and 10 min in the case of mERhigh or 6 min in the case of mER-
low cells). The asterisks indicate the significant reduction in ERK1/2 activation compared with cells treated only with E2 (black bars).Breast Cancer Research    Vol 7 No 1    Zivadinovic and Watson 
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fection manipulations to over-express receptor (with prob-
able accompanying altered regulatory parameters). Our
experimental model avoids changes in stoichiometry of the
multiple interacting proteins that are involved in steroid
actions. Because our mERhigh and mERlow cells were not
clonally derived (from a single cell), the observed differ-
ences between these subpopulations cannot be attributed
to clonal variations.
A characteristic punctate staining for mER (earlier reported
for GH3/B6/F10 cells [22]) was also detected on the sur-
face of most of our mERhigh MCF-7 cells. MCF-7 mERlow
cells also had occasional punctuate staining, but at a much
lower level. Because it is difficult and time-consuming to
quantify this staining via immunocytochemistry, we modi-
fied our previously developed 96-well plate immunoassay
[23] to measure both membrane and intracellular receptors
in breast cancer cells, and to quantitate the relative
amounts in these two receptor subpopulations. This assay
must be tailored to specific cell types to ensure
preservation of the membranes (which have quite different
compositions in different cell types) and to optimize for dif-
ferent antibody labeling systems. Although mER-α levels
differed between the two cell types named for these
differences (high versus low), we discovered that the two
subpopulations had the same quantity of total receptor
(measured in permeabilized cells). This finding is consistent
with intracellular and membrane fractions of ER-α being
from the same ER pool, but with a different balance of sub-
cellular distribution.
There is disagreement in the literature on the expression of
caveolin-1 and -2 in MCF-7 cells. To test whether mER is
localized in caveolar membranes, we had first to resolve
this uncertainty. Some have reported that in MCF-7 cells
caveolin-1 is downregulated and only caveolin-2 is
expressed [36,37]. Others reported that caveolin-1 could
be upregulated and downregulated in MCF-7 cells in con-
cert with the cells' ability to develop drug resistance [38].
Some studies used transient transfection to re-express the
missing caveolin-1 and test for its function in signaling
[7,39]. Apparently, there are several different subpopula-
tions of MCF-7 cells growing in different laboratories
Figure 8
Dose-dependent 17β-estradiol (E2) activation of extracellular signal- regulated kinase (ERK)1/2 in membrane estrogen receptor (mER)-α- enriched (mERhigh) versus mER-α-depleted (mERlow) MCF-7 cells Dose-dependent 17β-estradiol (E2) activation of extracellular signal-
regulated kinase (ERK)1/2 in membrane estrogen receptor (mER)-α-
enriched (mERhigh) versus mER-α-depleted (mERlow) MCF-7 cells. Cells 
were incubated with different E2 concentrations at peak activation 
times: (a) 10 min in the case of mERhigh and (b) 6 min in the case of 
mERlow. The experiments were repeated three times, each with 16 repli-
cates; values are expressed as mean ± standard error. The asterisks 
indicate significant differences from the vehicle controls (C).
Figure 9
Pulsed effect of 17β-estradiol (E2) and conjugated E2 on cell  proliferation Pulsed effect of 17β-estradiol (E2) and conjugated E2 on cell prolifera-
tion. MCF-7 membrane estrogen receptor (mER)-α-enriched (mERhigh) 
MCF-7 cells were treated for 5 days (bar 1) or 10 min with 1 pmol/l E2 
(bar 2) or E2-peroxidase containing the equivalent of 1 pmol/l E2 (bar 3). 
In bar 4, pretreatment with U0126 (40 µmol/l) for 15 min was followed 
by 10 min treatment with E2. Bar 5 shows blockage of mER-α by incu-
bating the cells for 1 hour at room temperature with 1 µg/ml of a ligand 
binding domain-specific antibody and the subsequent effect of 10 min 
incubation with E2. These experiments were repeated three times, each 
with 40 well replicates; values are expressed as mean ± standard error. 
The asterisks indicate significant differences from the controls (C – eth-
anol vehicle, inhibitor, or antibody treatment alone).Available online http://breast-cancer-research.com/content/7/1/R130
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[40,41]. Our MCF-7 cells expressed both caveolin-1 and -
2, and ER-α was associated with the same gradient frac-
tions in which most of the caveolin proteins were detected.
A 67 kDa ER and a variant of lower molecular weight (52
kDa) were detected in both the cell lysate and the caveolar
membrane gradient fractions. Until recently the lower
molecular weight ER variants were thought to be proteo-
lytic fragments, but evidence that some of those molecules
are truncated products of the full-length ER-α was recently
presented. It is well documented that in MCF-7 breast can-
cer cells ER-α mRNA can undergo alternative splicing, gen-
erating transcripts with single, double, or multiple exon
deletions [42], and that a 52 kDa protein is translated from
the predominant splice variant mRNA that is missing exon
7 [43]. Others have identified a 46 kDa variant in human
endothelial cells [44] and in MCF-7 cells [45,46]. Some
evidence suggests that the 46 kDa receptor is the major
functional membrane form of ER [44]; however, the precise
functions of the truncated ER-αs are still under
investigation.
The traditional detection and quantitation of phosphor-
ylated MAPKs via Western blot analysis is laborious and
somewhat arbitrary in the designation of appropriate densi-
tometric backgrounds for comparison, especially in situa-
tions where the significant activation response is not large.
We developed an enzyme-linked immunosorbent assay to
deal with these experimental problems using fixed cells
[47], which allowed convenient testing of large numbers of
different conditions. Ours is the first report that different
levels of mER in MCF-7 cells influence the different tempo-
ral and dose-dependent estrogen-induced phosphoryla-
tions of ERKs. The subpopulation of cells with high mER
levels exhibited early and more robust activation, peaking at
10 min with a reactivation at 60 min, whereas the subpop-
ulation of cells with low mER levels were only capable of
weakly activating ERKs at one early time point (6 min). Fur-
thermore, in the ER-α-negative cell line MDA-MB-231, E2
could not activate these kinases. The physiologic signifi-
cance of early ERK1/2 activation was confirmed by show-
ing that short pulse E2  treatment also stimulated cell
proliferation. We and others [46] have confirmed that mER-
α in breast cancer cells is responsible for this effect by
showing that E2-peroxidase can stimulate proliferation and
that this effect can be abolished by prior blocking of ER-α
with ligand-binding domain-specific antibody.
The inability to activate ERKs with E2 in an ER-α-negative
cell line, and the ability to do so in MCF-7 ER-α-positive
cells, was assigned by others to the orphan G-protein-cou-
pled receptor GPR30 [48]. However, recent studies with
antisense GPR30 knockdowns revealed that E2-stimulated
MCF-7 cells proliferate as well as cells with normal levels of
GPR30 [49,50]. ERK activation associated with the ability
of these cells to respond to estrogens by proliferating thus
does not appear to be a function of GPR30 levels.
Different levels of mER also determined the E2  dose-
dependent phosphorylation of ERKs. Cells with low levels
of mER responded to a limited range of concentrations (10-
13 to 10-12 mol/l). However, mERhigh cells responded to a
much wider range of E2 concentrations (10-13 to 10-7 mol/l)
with a declining (but still significant) ERK activation at 10–
100 nmol/l E2. This finding corresponds to our observation
that 10 nmol/l and higher E2 decreases cell proliferation in
mERhigh MCF-7 cells, and is consistent with the idea that E2
induces cAMP-activated protein kinase A inhibition of
MAPK pathways at these higher concentrations (see
accompanying paper [28]). Activation of ERKs has been
linked to the proliferative cellular response [51]. Our
accompanying report [28] addresses other rapid estrogen-
elicited signaling responses that, in concert with ERK acti-
vation, can affect and perhaps balance cell proliferation
responses.
Figure 10
Effects of phosphatase inhibitors on extracellular signal-regulated  kinase (ERK)1/2 dephosphorylation Effects of phosphatase inhibitors on extracellular signal-regulated 
kinase (ERK)1/2 dephosphorylation. Cells were pretreated for 1 hour 
with different phosphatase inhibitors: 50 nmol/l okadaic acid (OA) or 3 
µmol/l cyclosporin A (CyclA). Then, ERK1/2 phosphorylation was 
determined after 1 pmol/l E2 stimulation for (a, b) 20 min or (c) 60 min. 
Black bars are membrane estrogen receptor (mER)-α-enriched (mER-
high) MCF-7 cells; open bars are mER-α-depleted (mERlow) MCF-7 
cells. The data are averages of two or three experiments, each with 24 
replicates; values are expressed as mean ± standard error. The aster-
isks indicate significant differences from the vehicle control-treated 
samples with corresponding inhibitor included.Breast Cancer Research    Vol 7 No 1    Zivadinovic and Watson 
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The classical antiestrogen ICI182,780 has been well
defined as an antagonist of the action of estrogen at the
transcriptional level. In our studies this compound was also
a potent and rapid ERK activator. With different kinetics,
the transcriptionally inactive 17α-estradiol also activated
ERKs. It has been demonstrated that pure antiestrogen–ER
complex can bind to estrogen response elements, but that
the resultant transcriptional unit is inactive [52]. This
binding and inactivation is generally used for pharmacolog-
ical identification of ER-α participation in gene transcrip-
tion. However, in a yeast reporter system antiestrogens
(ICI182,780 and tamoxifen) induce ER dimerization and
transcriptional activity [53]. Thus, although the published
data disagree, it remains possible that antiestrogen–ER
complexes can exert rapid effects such as induction of ERK
phosphorylation and other signaling effects [54,55].
Other differences between findings may stem from effects
assessed at different time points [56-58]. The length of
time between estrogen or antiestrogen administration and
kinase assessment can clearly influence outcomes, as evi-
denced by our time- and compound sequencing-depend-
ent changes in ERK activation. It is also known that lengthy
exposures to ICI182,780 can dramatically decrease ER-α
protein levels [47,52], which could explain the decreased
ERK activation observed in some studies. Long-term estro-
gen-deprived MCF-7 cells express higher levels of ER than
do wild-type MCF-7 cells and are hypersensitive to E2;
ICI182,780 did not alter the pattern of response to E2-stim-
ulated growth in these cells [59,60]. To reconcile this
observation with the expected inhibitory effect of
ICI182,780, the authors suggested that ICI182,780
blocked only the effect of the residual E2 coming from plas-
tic tissue culture flasks, without affecting the added E2. We
can speculate that the observed effect of ICI182,780 was
genuine and resulted from potentially increased levels of
mER in long-term estrogen deprived MCF-7 cells, because
our previous studies suggested that serum deprivation ele-
vates mER-α levels [61]. In other cell types ICI182,780
behaved as a potent agonist of ERK1/2 activation (e.g. in
rat cerebellar neurons expressing plasmid-generated ERs
[60]), or as a partial ER agonist (in the superficial stroma
and glandular epithelium of the sheep uterine endometrium
[62]). It is likely that subtle differences in the shape of estro-
gen- and antiestrogen-liganded ERs, whether nuclear or
membrane, present different interaction platforms for a vari-
ety of co-modulators, and that each signaling pathway must
Figure 11
Effects of ICI182,780 (ICI), ICI + 17β-estradiol (E2), and 17α-estradiol on extracellular signal-regulated kinase (ERK)1/2 activation in membrane  estrogen receptor-α-enriched (mERhigh) MCF-7 cells Effects of ICI182,780 (ICI), ICI + 17β-estradiol (E2), and 17α-estradiol on extracellular signal-regulated kinase (ERK)1/2 activation in membrane 
estrogen receptor-α-enriched (mERhigh) MCF-7 cells. (a) Time course of ERK1/2 activation by 1 µmol/l ICI. (b) Pretreatment with ICI (1 µmol/l) for 
30 min followed by 1 pmol/l E2 stimulation in the continued presence of ICI. (c) ICI (1 µmol/l) and E2 (1 pmol/l) applied simultaneously. (d) Time 
course of 17α-estradiol (10 nmol/l) activation of ERK1/2. All experiments were repeated at least three times with 24 well replicates/experiment; the 
averaged values ± standard error are presented. The asterisks indicate significant differences from vehicle controls.Available online http://breast-cancer-research.com/content/7/1/R130
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be considered in the context of a particular cell type's rep-
ertoire of partnering proteins.
In addition to having positive effects by itself, ICI182,780
was able to alter the E2 response differently, dependent on
the timing of its administration. If the cells were pretreated
for only 30 min (the time point when ICI182,780 alone did
not change basal ERK activation), then the initial E2 activa-
tion and the late re-activation at 60 min were preserved,
whereas the after-peak deactivation was enhanced. If
ICI182,780 and E2 were added simultaneously, then the
activation was delayed to 20 min, but weakly persisted up
to 1 hour. Similar observations that ICI182,780 can change
the time of ERK activation were reported in the case of a
human thyroid carcinoma cell line, in which it reduced the
30 min to 1 hour activation, but enhanced later sustained
activation at 6 hours [63]. The same authors showed that,
in differentiated thyroid gland carcinoma cells (XTC133),
addition of ICI182,780 induces a small decrease in the
sustained ERK phosphorylation. Thus, in addition to dem-
onstrating that ICI182,780 is not just an antagonist for this
response, these studies and ours may point to cell-specific
differences in ERK regulation.
Phosphorylations leading to activation and subsequent
inactivation of proteins are important regulatory mecha-
nisms for control of cell growth and differentiation [64,65].
Although ERKs are thought to play a key role in cell prolif-
eration, it has been suggested that persistent activation of
ERKs might result in cell cycle arrest and differentiation in
PC12 cells, or cell growth inhibition and apoptosis in nor-
mal rat hepatocytes and several human tumor cell lines
[65]. However, a detailed time course and transient ERK
activations, interspersed with phosphatase-mediated inac-
tivations, are rarely addressed. We (in the present study)
and others [66] showed that the serine/threonine phos-
phatases PP1 and PP2A participate in the dephosphoryla-
tion of ERKs. It is interesting that OA (a PP1 and PP2A
inhibitor) was more effective in mERhigh  cells, whereas
cyclosporin A (a PP2B inhibitor) was almost equally effi-
cient in both cell populations. These data suggest that the
level of mER-α expression/activation can be associated
with activation of different types of ERK-modulating phos-
phatases. Other phosphatases, such as tyrosine phos-
phatase and dual specificity phosphatases (which
dephosphorylate tyrosine, threonine, and serine residues),
have been implicated in ERK dephosphorylation [67,68]
and will be the subject of our future studies.
Additional studies of ERK activations, deactivations, and
stability will be needed before we can formulate a more glo-
bal picture of the post-translational modifications that lead
to function of this important group of regulators in prolifer-
ation and differentiation. However, it is clear that nong-
enomic estrogen actions and the membrane receptors
through which they act participate in this regulation.
Conclusion
E2-induced changes in breast cancer cell number [28] can
be directly related to ERK1/2 activation/deactivation pat-
terns and interacting signaling mechanisms. The differential
behavior of cell lines expressing different levels of mER-α
suggests a role for this receptor in the temporal
coordination of phosphorylation/dephosphorylation events
affecting the mitogen-activated kinases ERK1 and ERK2.
Competing interests
The author(s) declare that they have no competing
interests.
Acknowledgements
We thank Dr David Konkel for critically reviewing this paper and Dr 
Bahiru Gametchu for assistance in the FACS separation of cell subpop-
ulations. This work was supported by grants # DAMD17-01-1-0418 
and #DAMD17-01-1-0649 from Department of Defense Breast Cancer 
Research Program.
References
1. Tsai MJ, O'Malley BW: Molecular mechanisms of action of ster-
oid/thyroid receptor superfamily members. Annu Rev Biochem
1994, 63:451-486.
2. Watson CS, Gametchu B: Proteins of multiple classes partici-
pate in nongenomic steroid actions. Exp Biol Med (Maywood)
2003, 228:1272-1281.
3. Watson CS, Gametchu B: Membrane-initiated steroid actions
and the proteins that mediate them. Proc Soc Exp Biol Med
1999, 220:9-19.
4. Farach-Carson MC, Davis PJ: Steroid hormone interactions with
target cells: cross talk between membrane and nuclear
pathways. J Pharmacol Exp Ther 2003, 307:839-845.
5. Watson CS: The Identities of Membrane Steroid Receptors ... and
Other Proteins Mediating Nongenomic Steroid Action Boston:
Kluwer Academic Publishers; 2003. 
6. Shaul PW: Regulation of endothelial nitric oxide synthase:
location, location, location.  Annu Rev Physiol 2002,
64:749-774.
7. Razandi M, Oh P, Pedram A, Schnitzer J, Levin ER: ERs associate
with and regulate the production of caveolin: implications for
signaling and cellular actions.  Mol Endocrinol 2002,
16:100-115.
8. Watson CS, Gametchu B: Membrane-initiated steroid actions
and the proteins which mediate them [review]. Proc Soc Exp
Biol Med 1999, 220:9-19.
9. Russell KS, Haynes MP, Sinha D, Clerisme E, Bender JR: Human
vascular endothelial cells contain membrane binding sites for
estradiol, which mediate rapid intracellular signaling. Proc Natl
Acad Sci USA 2000, 97:5930-5935.
10. Endoh H, Sasaki H, Maruyama K, Takeyama K, Waga I, Shimizu T,
Kato S, Kawashima H: Rapid activation of MAP kinase by estro-
gen in a bone cell line. Biochem Biophys Res Commun 1997,
235:99-102.
11. Watters JJ, Campbell JS, Cunningham MJ, Krebs EG, Dorsa DM:
Rapid membrane effects of steroids in neuroblastoma cells:
effects of estrogen and mitogen activated protein kinase sig-
nalling cascade and C-FOS immediate early gene
transcription. Endocrinology 1997, 138:4030-4033.
12. Migliaccio A, Di Domenico M, Castoria G, De Falco A, Bontempo
P, Nola E, Auricchio F: Tyrosine kinase/P21(RAS)/MAP-kinase
pathway activation by estradiol-receptor complex in MCF-7
cells. EMBO J 1996, 15:1292-1300.Breast Cancer Research    Vol 7 No 1    Zivadinovic and Watson 
R143
13. Razandi M, Pedram A, Park ST, Levin ER: Proximal events in sig-
naling by plasma membrane estrogen receptors. J Biol Chem
2003, 278:2701-2712.
14. Zhang Z, Maier B, Santen RJ, Song RX: Membrane association
of estrogen receptor alpha mediates estrogen effect on MAPK
activation. Biochem Biophys Res Commun 2002, 294:926-933.
15. Pappas TC, Gametchu B, Yannariello-Brown J, Collins TJ, Watson
CS: Membrane estrogen receptors in GH3/B6 cells are asso-
ciated with rapid estrogen-induced release of prolactin. Endo-
crine 1994, 2:813-822.
16. Pappas TC, Gametchu B, Watson CS: Membrane estrogen
receptor-enriched GH3/B6 cells have an enhanced non-
genomic response to estrogen. Endocrine 1995, 3:743-749.
17. Pappas TC, Gametchu B, Watson CS: Membrane estrogen
receptors identified by multiple antibody labeling and
impeded-ligand binding. FASEB J 1995, 9:404-410.
18. Norfleet AM, Clarke C, Gametchu B, Watson CS: Antibodies to
the estrogen receptor-a modulate prolactin release from rat
pituitary tumor cells through plasma membrane estrogen
receptors. FASEB J 2000, 14:157-165.
19. English J, Pearson G, Wilsbacher J, Swantek J, Karandikar M, Xu
S, Cobb MH: New insights into the control of MAP kinase
pathways. Exp Cell Res 1999, 253:255-270.
20. Gametchu B: Glucocorticoid receptor-like antigen in lym-
phoma cell membranes: correlation to cell lysis. Science 1987,
236:456-461.
2 1. G am et c hu  B,  W at s on  C ,  S hi h C , D as h ew  B :  Studies on the
arrangement of glucocorticoid receptors in the plasma mem-
brane of S-49 lymphoma cells. Steroids 1991, 56:411-419.
22. Norfleet AM, Thomas ML, Gametchu B, Watson CS: Estrogen
receptor-a detected on the plasma membrane of aldehyde-
fixed GH3/B6/F10 rat pituitary tumor cells by enzyme-linked
immunocytochemistry. Endocrinology 1999, 140:3805-3814.
23. Campbell CH, Watson CS: A comparison of membrane vs.
intracellular estrogen receptor-alpha in GH3/B6 pituitary
tumor cells using a quantitative plate immunoassay. Steroids
2001, 66:727-736.
24. Campbell CH, Bulayeva N, Brown DB, Gametchu B, Watson CS:
Regulation of the membrane estrogen receptor-α: role of cell
density, serum, cell passage number, and estradiol. FASEB J
2002, 16:1917-1927.
25. Song KS, Li SW, Okamoto T, Quilliam LA, Sargiacomo M, Lisanti
MP: Co-purification and direct interaction of Ras with caveolin,
an integral membrane protein of caveolae microdomains:
detergent-free purification of caveolae membranes.  J Biol
Chem 1996, 271:9690-9697.
26. Bulayeva NN, Gametchu B, Watson CS: Quantitative measure-
ment of estrogen-induced ERK 1 and 2 activation via multiple
membrane-initiated signaling pathways.  Steroids 2004,
69:181-192.
27. Lottering M-L, Haag M, Seegers JC: Effects of 17β-estradiol
metabolites on cell cycle events in MCF-7 cells. Cancer Res
1992, 52:5926-5932.
28. Zivadinovic D, Gametchu B, Watson CS: Membrane estrogen
receptor-α levels in MCF-7 breast cancer cells predict cAMP
and proliferation responses.  Breast Cancer Res 2004,
7:R101-R112.
29. Lobenhofer EK, Marks JR: Estrogen-induced mitogenesis of
MCF-7 cells does not require the induction of mitogen-acti-
vated protein kinase activity. J Steroid Biochem Mol Biol 2000,
75:11-20.
30. Wera S, Hemmings BA: Serine/threonine protein
phosphatases. Biochem J 1995, 311:17-29.
31. Boe R, Gjertsen BT, Vintermyr OK, Houge G, Lanotte M, Doskel-
and SO: The protein phosphatase inhibitor okadaic acid
induces morphological-changes typical of apoptosis in
mammalian-cells. Exp Cell Res 1991, 195:237-246.
32. Cohen P, Holmes CF, Tsukitani Y: Okadaic acid: a new probe for
the study of cellular regulation.  Trends Biochem Sci 1990,
15:98-102.
33. Pietras RJ, Szego CM: Specific binding sites for oestrogen at
the outer surfaces of isolated endometrial cells. Nature 1977,
265:69-72.
34. Berthois Y, Pourreau-Schneider N, Gandilhon P, Mittre H, Tubiana
N, Martin PM: Estradiol membrane binding sites on human
breast cancer cell lines. Use of a fluorescent estradiol conju-
gate to demonstrate plasma membrane binding systems. J
Steroid Biochem 1986, 25:963-972.
35. Germain PS, Metezeau P, Tiefenauer LX, Kiefer H, Ratinaud MH,
Habrioux G: Use of a biotinyl-estradiol derivative to demon-
strate estradiol-membrane binding sites on adherent human
breast cancer MCF-7 cells.  Anticancer Res 1993,
13:2347-2354.
36. Sager R, Sheng S, Anisowicz A, Sotiropoulou G, Zou Z, Stenman
G, Swisshelm K, Chen Z, Hendrix MJ, Pemberton P: RNA genetics
of breast cancer: Maspin as paradigm. Cold Spring Harb Symp
Quant Biol 1994, LIX:537-546.
37. Engelman JA, Zhang X, Galbiati F, Volonte D, Sotgia F, Pestell RG,
Minetti C, Scherer PE, Okamoto T, Lisanti MP: Molecular genet-
ics of the caveolin gene family: implications for human can-
cers, diabetes, Alzheimer disease, and muscular dystrophy.
Am J Hum Genet 1998, 63:1578-1587.
38. Lavie Y, Fiucci G, Liscovitch M: Up-regulation of caveolae and
caveolar constituents in multidrug-resistant cancer cells. J Biol
Chem 1998, 273:32380-32383.
39. Scherer PE, Lewis RY, Volonte D, Engelman JA, Galbiati F, Couet
J, Kohtz DS, van Donselaar E, Peters P, Lisanti MP: Cell-type and
tissue-specific expression of caveolin-2. Caveolins 1 and 2 co-
localize and form a stable hetero-oligomeric complex in vivo.
J Biol Chem 1997, 272:29337-29346.
40. Jensen J, Kitlen JW, Briand P, Labrie F, Lykkesfeldt AE: Effect of
antiestrogens and aromatase inhibitor on basal growth of the
human breast cancer cell line MCF-7 in serum-free medium. J
Steroid Biochem Mol Biol 2003, 84:469-478.
41. Santen R, Jeng MH, Wang JP, Song R, Masamura S, McPherson
R, Santner S, Yue W, Shim WS: Adaptive hypersensitivity to
estradiol: potential mechanism for secondary hormonal
responses in breast cancer patients. J Steroid Biochem Mol
Biol 2001, 79:115-125.
42. Poola I, Koduri S, Chatra S, Clarke R: Identification of twenty
alternatively spliced estrogen receptor alpha mRNAs in breast
cancer cell lines and tumors using splice targeted primer
approach. J Steroid Biochem Mol Biol 2000, 72:249-258.
43. Fasco MJ, Keyomarsi K, Arcaro KF, Gierthy JF: Expression of an
estrogen receptor alpha variant protein in cell lines and
tumors. Mol Cell Endocrinol 2000, 162:167-180.
44. Li L, Haynes MP, Bender JR: Plasma membrane localization and
function of the estrogen receptor alpha variant (ER46) in
human endothelial cells.  Proc Natl Acad Sci USA 2003,
100:4807-4812.
45. Flouriot G, Brand H, Denger S, Metivier R, Kos M, Reid G, Son-
ntag-Buck V, Gannon F: Identification of a new isoform of the
human estrogen receptor-alpha (hER-alpha) that is encoded
by distinct transcripts and that is able to repress hER-alpha
activation function 1. EMBO J 2000, 19:4688-4700.
46. Marquez DC, Pietras RJ: Membrane-associated binding sites
for estrogen contribute to growth regulation of human breast
cancer cells. Oncogene 2001, 20:5420-5430.
47. Bulayeva N, Gametchu B, Watson CS: Quantitative measure-
ment of MAP kinase activation by estrogens via multiple sign-
aling pathways. Steroids 2004 in press.
48. Filardo EJ, Quinn JA, Bland KI, Frackelton AR: Estrogen-induced
activation of Erk-1 and Erk-2 requires the G protein-coupled
receptor homolog, GPR30, and occurs via trans-activation of
the epidermal growth factor receptor through release of HB-
EGF. Mol Endocrinol 2000, 14:1649-1660.
49. Ahola TM, Manninen T, Alkio N, Ylikomi T: G protein-coupled
receptor 30 is critical for a progestin-induced growth inhibition
in MCF-7 breast cancer cells.  Endocrinology 2002,
143:3376-3384.
50. Ahola TM, Purmonen S, Pennanen P, Zhuang YH, Tuohimaa P,
Ylikomi T: Progestin upregulates G-protein-coupled receptor
30 in breast cancer cells. Eur J Biochem 2002, 269:2485-2490.
51. Chang FM, Steelman LS, Shelton JG, Lee JT, Navolanic PM, Bla-
lock WL, Franklin R, McCubrey JA: Regulation of cell cycle pro-
gression and apoptosis by the Ras/Raf/MEK/ERK pathway. Int
J Oncol 2003, 22:469-480.
52. Pink JJ, Jordan VC: Models of estrogen receptor regulation by
estrogens and antiestrogens in breast cancer cell lines. Can-
cer Res 1996, 56:2321-2330.
53. Dudley MW, Sheeler CQ, Wang H, Khan S: Activation of the
human estrogen receptor by the antiestrogens ICI 182,780
and tamoxifen in yeast genetic systems: implications for theirAvailable online http://breast-cancer-research.com/content/7/1/R130
R144
mechanism of action.  Proc Natl Acad Sci USA 2000,
97:3696-3701.
54. Aronica SM, Kraus WL, Katzenellenbogen BS: Estrogen action
via the cAMP signaling pathway: stimulation of adenylate
cyclase and cAMP-regulated gene transcription.  Proc Natl
Acad Sci USA 1994, 91:8517-8521.
55. Kiefer T, Ram PT, Yuan L, Hill SM: Melatonin inhibits estrogen
receptor transactivation and cAMP levels in breast cancer
cells. Breast Cancer Res Treat 2002, 71:37-45.
56. Keshamouni VG, Mattingly RR, Reddy KB: Mechanism of 17-
beta-estradiol-induced Erk1/2 activation in breast cancer
cells. A role for HER2 AND PKC-delta.  J Biol Chem 2002,
277:22558-22565.
57. Improta-Brears T, Whorton AR, Codazzi F, York JD, Meyer T,
McDonnell DP: Estrogen-induced activation of mitogen-acti-
vated protein kinase requires mobilization of intracellular
calcium. Proc Natl Acad Sci USA 1999, 96:4686-4691.
58. Varma H, Conrad SE: Antiestrogen ICI 182,780 decreases pro-
liferation of insulin-like growth factor I (IGF-I)-treated MCF-7
cells without inhibiting IGF-I signaling.  Cancer Res 2002,
62:3985-3991.
59. Yue W, Wang JP, Conaway M, Masamura S, Li Y, Santen RJ: Acti-
vation of the MAPK pathway enhances sensitivity of MCF-7
breast cancer cells to the mitogenic effect of estradiol. Endo-
crinology 2002, 143:3221-3229.
60. Wong JK, Le HH, Zsarnovszky A, Belcher SM: Estrogens and
ICI182,780 (Faslodex) modulate mitosis and cell death in
immature cerebellar neurons via rapid activation of p44/p42
mitogen-activated protein kinase.  J Neurosci 2003,
23:4984-4995.
61. Watson CS, Pappas TC, Gametchu B: The other estrogen
receptor in the plasma membrane: implications for the actions
of environmental estrogens.  Environ Health Perspect 1995,
103(Suppl 7):41-50.
62. Robertson JA, Zhang Y, Ing NH: ICI 182,780 acts as a partial
agonist and antagonist of estradiol effects in specific cells of
the sheep uterus.  J Steroid Biochem Mol Biol 2001,
77:281-287.
63. Manole D, Schildknecht B, Gosnell B, Adams E, Derwahl M:
Estrogen promotes growth of human thyroid tumor cells by
different molecular mechanisms.  J Clin Endocrinol Metab
2001, 86:1072-1077.
64. Cohen P: The regulation of protein function by multisite phos-
phorylation: a 25 year update.  Trends Biochem Sci 2000,
25:596-601.
65. Carr BI, Wang Z, Kar S: K vitamins, PTP antagonism, and cell
growth arrest. J Cell Physiol 2002, 193:263-274.
66. Pawlowski M, Ragab A, Rosa JP, Bryckaert M: Selective dephos-
phorylation of the threonine(183) residue of ERK2 upon
(alpha)llb(beta)3 engagement in platelets.  FEBS Lett 2002,
521:145-151.
67. Camps M, Nichols A, Arkinstall S: Dual specificity phos-
phatases: a gene family for control of MAP kinase function.
FASEB J 2000, 14:6-16.
68. Zhang ZY, Zhou B, Xie L: Modulation of protein kinase signaling
by protein phosphatases and inhibitors. Pharmacol Ther 2002,
93:307-317.